SCHEMBL6926207

SCHEMBL6926207

CCOP(=O)(OCC)c1cc2cc(S(=O)(=O)Cl)c(Cl)cc2[nH]c1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 9/20 0.38
GRIN2D O15399 4/20 0.38
GRIN3B O60391 4/20 0.38
GRIN2A Q12879 4/20 0.38
GRIN2B Q13224 4/20 0.38
GRIN2C Q14957 4/20 0.38
GRIN3A Q8TCU5 4/20 0.38
GCK P35557 1/20 0.31
GRIA1 P42261 3/20 0.31
GRIA2 P42262 3/20 0.31
GRIA3 P42263 3/20 0.31
GRIA4 P48058 3/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
CYP1A2 P05177 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6926873 0.89 USP2 (0.38) GRIN1GRIN2DGRIN3BGRIN2AGRIN2B
SCHEMBL7647652 0.89 KDM4E (0.38) GRIN1GRIN2DGRIN3BGRIN2AGRIN2B
SCHEMBL7650412 0.87 TSHR (0.37) GRIN1GRIN2DGRIN3BGRIN2AGRIN2B
SCHEMBL7647190 0.87 GRIN1 (0.35) GRIN1GRIN2DGRIN3BGRIN2AGRIN2B
SCHEMBL6926884 0.87 GRIN2D (0.31) GRIN1GRIN2DGRIN3BGRIN2AGRIN2B
SCHEMBL7648020 0.86 GRIN1 (0.35) GRIN1GRIN2DGRIN3BGRIN2AGRIN2B
SCHEMBL7646322 0.85 GRIN1 (0.34) GRIN1GRIN2DGRIN3BGRIN2AGRIN2B
SCHEMBL7651560 0.85 ALDH1A1 (0.36) GRIN1GRIN2DGRIN3BGRIN2AGRIN2B
SCHEMBL7647829 0.85 POLB (0.37) GRIN1GRIN2DGRIN3BGRIN2AGRIN2B
SCHEMBL7645904 0.85 GSTO1 (0.34) GRIN1GRIN2DGRIN3BGRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6596709-B1 For treatment of Alzheimer's disease, schizophrenia, amyotrophic lateral sclerosis, and Huntington's chorea LES LABORATOIRES SERVIER (FR) 2003-07-22 US disclosed
US-6518258-B1 6-sulphamoyl -3-quinolyphosphonic acid compounds LES LABORATOIRES SERVIER (FR) 2003-02-11 US disclosed
US-6486143-B2 NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS LES LABORATOIRES SERVIER (FR) 2002-11-26 US disclosed
CN-1320601-A 6-amino or 6-hydrazino-sulfonyl-3-quinolyl phosphonic acid compound, preparing process thereof and pharmaceutical composition contg. same ADIR (FR) 2001-11-07 CN disclosed
US-20010031746-A1 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds LES LABORATOIRES SERVIER (FR) 2001-10-18 US disclosed
CN-1317490-A Novel-6-sulfamine-3-quinolyl phosphonate compounds, its prepn. process and medical compsn. contg. them ADIR (FR) 2001-10-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031746-A1 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds CA6, P2RY6, FPR3 GRIN1 801/4885GRIN2D 1500/4885GRIN3B 919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.